Thrive will commercialise a blood test for multiple early-stage cancers based on research at Johns Hopkins University, following a series A round backed by Blue Cross and Blue Shield Association.
Thrive Earlier Detection, a US-based developer of a blood test for cancer, was spun out of Johns Hopkins University yesterday with $110m in series A funding from investors led by venture capital firm Third Rock Ventures.
BlueCross BlueShield Venture Partners, the corporate venturing subsidiary of health insurer Blue Cross and Blue Shield Association, participated in the round, as did molecular diagnostics company Exact Sciences.
Section 32, Casdin Capital, Biomatics Capital, Invus, Cowin Venture, Camden Partners, Gamma 3 and…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
